SCHEMBL17520325

SCHEMBL17520325

COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCCCCN(C)C

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 16/20 0.77
EGFR P00533 15/20 0.77
RET P07949 3/20 0.76
KIF5B P33176 3/20 0.76
FLT1 P17948 12/20 0.68
FGFR1 P11362 11/20 0.68
FLT4 P35916 10/20 0.68
PDGFRB P09619 3/20 0.67
FGFR2 P21802 2/20 0.67
FGFR4 P22455 2/20 0.67
FGFR3 P22607 2/20 0.67
TEK Q02763 2/20 0.62
BMPR1B O00238 1/20 0.62
PLK4 O00444 1/20 0.62
CIT O14578 1/20 0.62
GAK O14976 1/20 0.62
EPHB6 O15197 1/20 0.62
RIPK2 O43353 1/20 0.62
ROCK2 O75116 1/20 0.62
STK10 O94804 1/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17520351 0.97 KDR (0.78) KDREGFRRETKIF5BFLT1
SCHEMBL19220775 0.91 RET (0.64) KDREGFRRETKIF5BFLT1
SCHEMBL4109645 0.89 KDR (0.80) KDREGFRRETKIF5BFLT1
SCHEMBL9280 0.89 KDR (0.77) KDREGFRRETKIF5BFLT1
SCHEMBL1468281 0.88 KDR (0.82) KDREGFRRETKIF5BFLT1
SCHEMBL14964748 0.88 KDR (0.82) KDREGFRRETKIF5BFLT1
SCHEMBL19220777 0.88 RET (0.67) KDREGFRRETKIF5BFLT1
SCHEMBL7864780 0.87 KDR (0.83) KDREGFRRETKIF5BFLT1
SCHEMBL19006953 0.87 KDR (0.67) KDREGFRRETKIF5BFLT1
SCHEMBL5864525 0.87 KDR (1.00) KDREGFRRETKIF5BFLT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230322687-A1 SALT OF ARYLAMINOQUINAZOLINE-CONTAINING COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD (CN) 2023-10-12 US disclosed
US-20230322687-A1 SALT OF ARYLAMINOQUINAZOLINE-CONTAINING COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD (CN) 2023-10-12 US disclosed
EP-4219476-A1 SALT OF ARYLAMINOQUINAZOLINE-CONTAINING COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. (CN) 2023-08-02 EP disclosed
EP-3181554-B1 QUINAZOLINE DERIVATIVE CSPC ZHONGQI PHARMACEUTICAL TECH SHIJIAZHUANG CO LTD (CN) 2020-10-28 EP disclosed
EP-3181554-B1 QUINAZOLINE DERIVATIVE CSPC ZHONGQI PHARMACEUTICAL TECH SHIJIAZHUANG CO LTD (CN) 2020-10-28 EP disclosed
US-10774079-B2 Quinazoline derivative CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) 2020-09-15 US disclosed
US-10774079-B2 Quinazoline derivative CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) 2020-09-15 US disclosed
CN-106660970-B Quinazoline derivatives 石药集团中奇制药技术(石家庄)有限公司 2020-07-10 CN disclosed
US-10421754-B2 Quinazoline derivative CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) 2019-09-24 US disclosed
US-10421754-B2 Quinazoline derivative CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) 2019-09-24 US disclosed
US-20170226099-A1 QUINAZOLINE DERIVATIVE CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) 2017-08-10 US disclosed
US-20170226099-A1 QUINAZOLINE DERIVATIVE CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) 2017-08-10 US disclosed
US-20170226099-A1 QUINAZOLINE DERIVATIVE CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) 2017-08-10 US disclosed
EP-3181554-A1 QUINAZOLINE DERIVATIVE CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. (CN) 2017-06-21 EP disclosed
EP-3181554-A1 QUINAZOLINE DERIVATIVE CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. (CN) 2017-06-21 EP disclosed
WO-2016023330-A1 QUINAZOLINE DERIVATIVE 石药集团中奇制药技术(石家庄)有限公司 2016-02-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10774079-B2 Quinazoline derivative H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, TOP2A, TOP1 KDR 3669/4885EGFR 3701/4885RET 4595/4885
US-10421754-B2 Quinazoline derivative H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, TOP2A, TOP1 KDR 3669/4885EGFR 3701/4885RET 4595/4885
US-20170226099-A1 QUINAZOLINE DERIVATIVE H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, TOP2A, TOP1 KDR 3669/4885EGFR 3701/4885RET 4595/4885
US-20230322687-A1 SALT OF ARYLAMINOQUINAZOLINE-CONTAINING COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF WEE2, WEE1, CYP4F11 KDR 1406/4885EGFR 4056/4885RET 3039/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.